Extended Data Fig. 6: Monoclonal antibody ELISAs.
From: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
a, Graphs show anti-SARS-CoV-2 RBD antibody reactivity. ELISA EC50 values for all antibodies isolated from individuals who had recovered from COVID-19 assayed at 1.3 and 6.2 months after infection5,6 and 127 selected monoclonal antibodies isolated from 4 individuals who received the Moderna vaccine (black dots) and 4 who received the Pfizer–BioNTech vaccine (red dots), measured at 8 weeks after the boost. Red horizontal bars and indicated values represent geometric mean. Statistical significance was determined using two-tailed Mann–Whitney U test. b, c, Graphs show ELISA titration curves for 86 monoclonal antibodies isolated from individuals vaccinated with the Moderna vaccine (b) and 41 monoclonal antibodies isolated from individuals vaccinated with the Pfizer–BioNTech vaccine (c). d–l, Graphs show ELISA titrations for 84 antibodies isolated from individuals vaccinated with the Moderna vaccine against the indicated RBD variants. Isotype control and low-binding antibodies are indicated in colours. C661 is a nonbinding antibody. Data are representative of two independent experiments. m, Relative change in EC50 values for the indicated RBD variants over wild-type RBD of 84 antibodies isolated from individuals vaccinated with the Moderna vaccine. Red horizontal bars represent geometric mean. n, Heat-map summary of EC50 values for binding to wild-type RBD and the indicated mutant RBDs for 17 top neutralizing antibodies.
